Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lepidoglyphus destructor allergen extract skin prick test diagnostic study
2025-523426-40-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of lepidoglyphus destructor extract in Lepidoglyphus destructor allergy (2 arms), sponsored by Inmunotek. Planned start Sep 2026; status: authorised.
02
Drugs
lepidoglyphus destructor extract
03
Conditions
Lepidoglyphus destructor allergy
Beyond the preview
Go deeper on 2025-523426-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523426-40-00.